Making a case "for" focal therapy of the prostate in intermediate risk prostate cancer: Current perspective and ongoing trials

Basit Öğe Kaydı
dc.authorid0000-0003-0906-4417
dc.authorid0000-0002-6308-1763
dc.contributor.authorWang, Alex Z.
dc.contributor.authorLebastchi, Amir H.
dc.contributor.authorO'Connor, Luke P.
dc.contributor.authorAhdoot, Michael
dc.contributor.authorMehralivand, Sherif
dc.contributor.authorYerram, Nitin
dc.contributor.authorTaneja, Samir S.
dc.contributor.authorGeorge, Arvin K.
dc.contributor.authorSanchez-Salas, Rafael
dc.contributor.authorWard, John F.
dc.contributor.authordel Pilar Laguna Pes, Maria
dc.contributor.authorde la Rosette, Jean J. M. C. H.
dc.contributor.authorPinto, Peter A.
dc.date.accessioned2021-10-15T09:22:58Z
dc.date.available2021-10-15T09:22:58Z
dc.date.issued2021
dc.departmentİstanbul Medipol Üniversitesi, Uluslararası Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Üroloji Ana Bilim Dalı
dc.description.abstractFocal therapy is growing as an alternative management options for men with clinically localized prostate cancer. Parallel to the increasing popularity of active surveillance (AS) as a treatment for low-risk disease, there has been an increased interest towards providing focal therapy for patients with intermediate-risk disease. Focal therapy can act as a logical "middle ground" in patients who seek treatment while minimizing potential side effects of definitive whole-gland treatment. The aim of the current review is to define the rationale of focal therapy in patients with intermediate-risk prostate cancer and highlight the importance of patient selection in focal therapy candidacy.
dc.description.sponsorshipUnited States Department of Health & Human Services National Institutes of Health (NIH) - USA ; Doris Duke Charitable Foundation (DDCF) ; Roche Holding ; Genentech ; American Association for Dental Research ; Colgate-Palmolive Companyen_US
dc.identifier.citationWang, A. Z., Lebastchi, A. H., O'Connor, L. P., Ahdoot, M., Mehralivand, S., Yerram, N. ... Pinto, P. A. (2021). Making a case "for" focal therapy of the prostate in intermediate risk prostate cancer: Current perspective and ongoing trials. World Journal of Urology, 39(3), 729-739. https://dx.doi.org/10.1007/s00345-020-03525-0
dc.identifier.doi10.1007/s00345-020-03525-0
dc.identifier.endpage739
dc.identifier.issn0724-4983
dc.identifier.issn1433-8726
dc.identifier.issue3
dc.identifier.scopusqualityQ1
dc.identifier.startpage729
dc.identifier.urihttps://dx.doi.org/10.1007/s00345-020-03525-0
dc.identifier.urihttps://hdl.handle.net/20.500.12511/8457
dc.identifier.volume39
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofWorld Journal of Urologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectFocal Therapy
dc.subjectMRI
dc.subjectProstate Cancer
dc.titleMaking a case "for" focal therapy of the prostate in intermediate risk prostate cancer: Current perspective and ongoing trials
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
Ä°sim:
Laguna-Pilar-2021.pdf
Boyut:
667.05 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
Ä°ndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
Ä°sim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
Ä°ndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu